EcoDrugPlus

Sodium Voltage-Gated Channel Alpha Subunit 10

Ensembl ID : ENSLACG00000003090
Gene Symbol: SCN10A
2 Cross references
332 Possible Orthologues:

Sodium Voltage-Gated Channel Alpha Subunit 4

Ensembl ID : ENSLACG00000009665
Gene Symbol: SCN4A
4 Cross references
194 Possible Orthologues:

Sodium Voltage-Gated Channel Alpha Subunit 8

Ensembl ID : ENSLACG00000018890
Gene Symbol: SCN8A
3 Cross references
274 Possible Orthologues:

Solute Carrier Family 10 Member 2

Ensembl ID : ENSLACG00000008354
Gene Symbol: SLC10A2
2 Cross references
214 Possible Orthologues:

Solute Carrier Family 18 Member A2

Ensembl ID : ENSLACG00000013037
Gene Symbol: SLC18A2
4 Cross references
223 Possible Orthologues:

Solute Carrier Family 22 Member 6-A-Like

Ensembl ID : ENSLACG00000004792
Gene Symbol: LOC102366038
1 Cross references
345 Possible Orthologues:

Solute Carrier Family 22 Member 6-B-Like

Ensembl ID : ENSLACG00000004265
Gene Symbol: LOC102365521
1 Cross references
345 Possible Orthologues:

Solute Carrier Family 29 Member 1 (Augustine Blood Group)

Ensembl ID : ENSLACG00000011264
Gene Symbol: SLC29A1
4 Cross references
284 Possible Orthologues:

Solute Carrier Family 5 Member 1

Ensembl ID : ENSLACG00000017475
Gene Symbol: SLC5A1
4 Cross references
250 Possible Orthologues:

Solute Carrier Family 5 Member 2

Ensembl ID : ENSLACG00000007334
Gene Symbol: SLC5A2
4 Cross references
198 Possible Orthologues:

Solute Carrier Family 6 Member 1

Ensembl ID : ENSLACG00000019011
Gene Symbol: SLC6A1
4 Cross references
278 Possible Orthologues:

Solute Carrier Family 6 Member 2

Ensembl ID : ENSLACG00000014336
Gene Symbol: SLC6A2
4 Cross references
203 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).